CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
Edoxaban 30mg daily +1 moredrug
Likely dose
Edoxaban 30mg dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02339415
NCT02339415Phase 2Completed
CompareCT.gov

Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease

Hennepin Healthcare Research Institute·interventional·Posted Jan 15, 2015·Updated Sep 6, 2019

In Brief

A Phase 2 clinical trial evaluating Edoxaban 30mg daily and Matching placebo for Inflammation and 2 related conditions. Completed, enrolled 44 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Coagulation, HIV Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 15, 2015
Enrollment StartJul 1, 2015
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.5 years ago

Interventions

Edoxaban 30mg dailydrug

Matching placebodrug